Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

RTI Biologics Inc Issues FY, Q1 2013 Guidance Below Analysts' Estimates


Thursday, 7 Feb 2013 08:00am EST 

RTI Biologics Inc announced that for fiscal 2013, it expects revenues to be between $178-$182 million, net income per fully diluted share to be in the range of $0.17 to $0.19. For the first quarter of 2013, the Company expects revenues to be between $38 million and $39 million, and net income per fully diluted share to be approximately $0.02. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $189 million and EPS of $0.22 for fiscal 2013; revenue of $46 million and EPS of $0.05 for the first quarter of 2013. 

Company Quote

3.65
0.01 +0.27%
11:17am EDT